



Medicine Supply Notification

MSN/2025/068

Nifedipine (Adipine[®] XL) 30mg and 60mg modified-release tablets

Tier 2 – medium impact*

Date of issue: 19/12/2025

Link: [Medicines Supply Tool](#)

Summary

- Nifedipine (Adipine[®] XL) 30mg and 60mg modified-release tablets are out of stock until the end of January 2026.
- Alternative brands of nifedipine 30mg and 60mg modified-release tablets remain available, but only some can support increased demand, including Adanif[®] XL 30mg and 60mg modified-release tablets and Neozipine[®] XL 30mg modified-release tablets.
- Nifedipine (Coracten[®] XL) 30mg and 60mg modified-release capsules remain available and can support increased demand.
- Serious Shortage Protocols (SSP) for Adipine[®] XL 30mg and 60mg tablets were issued on 19/12/2025.

Actions Required

Prescribers should not initiate new patients on Adipine[®] XL 30mg and 60mg tablets until the supply issues have resolved.

Where existing patients have insufficient supplies of Adipine[®] XL 30mg or 60mg tablets to last until the re-supply date, prescribers should:

- consider prescribing alternative brands of nifedipine 30mg and 60mg modified-release tablets (that can support increased demand) at the equivalent dose (see Supporting information), advising patients of the change in brand; or
- consider prescribing Coracten[®] XL 30mg or 60mg capsules (see Supporting information), ensuring that the gelatin content is acceptable to patients, there is no intolerance to any of the excipients, and patients are counselled on the change in brand and formulation (and number of capsules per dose if applicable).

When switching between brands, patients may require closer monitoring initially to ensure blood pressure/angina symptoms remain controlled, and they should be advised to report any adverse effects.

Community pharmacists and dispensing doctors should:

- where a prescription for Adipine[®] XL 30mg tablets or Adipine[®] XL 60mg tablets is presented and cannot be fulfilled, supply an alternative preparation in accordance with [SSP084 and SSP085](#) for eligible patients;
- ensure patients are counselled on the change in brand and/or formulation; and
- if the patient is deemed ineligible or does not consent to receive an alternative product via the SSP, they should be promptly referred back to the prescriber.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Clinical Information

Adipine® XL 30mg and 60mg tablets and Coracten® XL 30mg and 60mg capsules are once daily modified-release nifedipine preparations, licensed for the treatment of hypertension and the prophylaxis of chronic stable angina pectoris. The capsule formulation may not be acceptable to some patients on cultural or religious grounds due to its gelatin content.

The BNF highlights that different versions of modified-release nifedipine preparations may not have the same clinical effect. To avoid confusion between these different formulations, prescribers should specify the brand to be dispensed.

Supply information

Table 1: Availability of nifedipine modified-release tablets/capsules

Nifedipine modified-release tablets/capsules that can support increased demand during the shortage of Adipine® XL 30mg tablets	Nifedipine modified-release tablets/capsules that can support increased demand during the shortage of Adipine® XL 60mg tablets	Nifedipine modified-release tablets/capsules that cannot support increased demand
Adanif® XL 30mg tablets Neozipine® XL 30mg tablets Coracten® XL 30mg capsules	Adanif® XL 60mg tablets Coracten® XL 60mg capsules Coracten® XL 30mg capsules (to be made up to the required dose)	Adalat® LA 30mg tablets Neozipine® XL 60mg tablets

Links to further information

[BNF Nifedipine](#)

[SmPC Adanif® XL](#)

[SmPC Adipine® XL](#)

[SmPC Coracten® XL](#)

[SmPC Neozipine® XL 30mg tablets](#)

[Serious shortage protocols \(SSPs\) | NHSBSA](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.